Best Biomanufacturing Podcasts (2025)

1
216: From Data Silos to Autonomous Biomanufacturing: Digital Twins and AI-Driven Scale-Up with Ilya Burkov - Part 2 18:33

Play Pause

11d ago18:33

18:33

Biomanufacturing has always dealt with the challenge of turning vast, complex datasets and intricate production steps into life-changing therapies. But when batch records multiply and process deviations loom, how do biotech teams make sense of it all? In this episode, we move beyond theory to the nuts and bolts of how AI - when thoughtfully deploye…

1
Combining AI With Operations Research To Advance Biomanufacturing With Tinglong Dai, Ph.D., and Tugce Martagan, Ph.D. 35:28

8d ago35:28

35:28

In this episode of “Better Biopharma,” host Tyler Menichiello is joined by Tinglong Dai, Ph.D., Bernard T. Ferrari Professor of Business at Johns Hopkins University, and Tugce Martagan, Ph.D., associate professor at Northeastern University, to talk about the potential advancements that can be made in biomanufacturing by combining AI with operations…

1
Johnson & Johnson’s hematology portfolio: breakthroughs to watch 34:25

7d ago34:25

34:25

Welcome to our final episode for 2025. We’re taking a little break for the holidays but we’ll be back again on Friday 9th of January to kick off our year with the Managing Director of Merck KGaA’s M Ventures, Hakan Goker. Today, though, I’m joined by Ester in t’Groen of Johnson & Johnson. Fresh off the American Society of Hematology (ASH) Annual Me…

1
The Power of Curiosity with Shuguang Zhang 1:17:30

7d ago1:17:30

1:17:30

In this special episode, we sit down with Shuguang Zhang, Head of the Laboratory of Molecular Architecture in the MIT Media Lab and a mentor to countless biotech explorers. His personal story has at least one literal "1 in 100 Million" moment and demonstrates the power of curiosity, kindness, and always asking questions. We trace how Shuguang's stu…

1
215: From Data Silos to Autonomous Biomanufacturing: Digital Twins and AI-Driven Scale-Up with Ilya Burkov - Part 1 21:34

13d ago21:34

21:34

Across biotech labs, researchers swim in oceans of process data: sensor streams, run records, engineering logs, and still, crucial decisions get stuck in spreadsheets or scribbled into fading notebooks. The challenge isn’t having enough information, it's knowing which actions actually move the needle in cell culture productivity, process stability,…

1
In Silico Modeling: A Drug Developer's Superpower 30:09

14d ago30:09

30:09

Developing complex biologics and advanced therapies is historically time-consuming and material-intensive—but computational modeling is reshaping the formulation landscape. In this episode of Life Science Solutions, host Chris Adkins is joined by Andrea Arsiccio, PhD, Senior Scientist and Team Lead In Silico at Coriolis Pharma, to discuss how in si…

1
109: 250th U.S. Anniversary 19:12

11d ago19:12

19:12

In commemoration of the 250th anniversary of the signing of the Declaration of Independence on July 4, 2026, Montco is holding a yearlong celebration during the 2025–2026 academic year featuring a vibrant series of events, activities, and reflections that connect our past to our present and future. Dr. Suzanne del Gizzo, Dean of Liberal Arts, will …

1
Tackling pulmonary fibrosis: Boehringer Ingelheim’s new drug + AI approach 38:47

14d ago38:47

38:47

In this episode we sit down with Martin Beck, Senior Vice President and Head of the Inflammation Business Unit at Boehringer Ingelheim. Martin grew up just down the road from the company’s headquarters in Germany, joined as a scholarship student more than 20 years ago, and never really left – and you’ll hear why he still loves it. We spend most of …

1
214: From Developability to Formulation: How In Silico Methods Predict Stability Issues Before the Lab with Giuseppe Licari - Part 2 14:49

18d ago14:49

14:49

Computational methods can predict stability issues before the lab. But how do you actually implement these approaches in your formulation workflow? From excipient selection to long-term stability prediction, in silico tools are transforming how biotech teams develop robust formulations while reducing costly trial-and-error cycles. In Part 2, Giusep…

1
Reimagining Bioreactors to Solve Manufacturing Bottlenecks with Brian Heligman 59:52

15d ago59:52

59:52

Biomanufacturing doesn’t fail for lack of clever biology; it stalls at the factory gate. We sit down with Biosphere CEO Brian Heligman to unpack how a materials scientist’s journey through batteries and perovskites led to a bold thesis for the bioeconomy: change the constraints of the bioreactor and you change everything downstream. Instead of mile…

1
213: From Developability to Formulation: How In Silico Methods Predict Stability Issues Before the Lab with Giuseppe Licari - Part 1 25:21

20d ago25:21

25:21

What if you could predict formulation failures before ever touching a pipette? Computational approaches are revolutionizing biologics development, replacing trial-and-error experimentation with predictive intelligence that catches stability issues early and accelerates your path from candidate selection to clinic. In this episode, David Brühlmann w…

1
Cracking Cancer’s Code: Transforming Research with Novel Cancer Models 29:47

21d ago29:47

29:47

Cancer is one of the biggest health challenges worldwide. While progress has been made, millions of patients are still in need of new treatment options that better address the complexities of their disease. BeOne Medicines is creating the world’s next-generation cancer treatments with relentless innovation, aiming to deliver therapies to more peopl…

1
212: When the Innovator Becomes the Patient: Manufacturing Reality vs. Patient Urgency with Jesús Zurdo - Part 2 22:13

21d ago22:13

22:13

What happens when cell therapy innovation meets real patient urgency? In this conversation, the barriers between scientist and patient all but vanish, bringing clarity—and a new sense of mission—to some of the biggest problems facing advanced therapy manufacturing and delivery. Meet Jesús Zurdo, a biotech leader whose three decades of experience in…

1
Building An Oral Vaccine Platform With Vaxart's Sean Tucker, Ph.D. 28:12

22d ago28:12

28:12

In this episode of “Better Biopharma,” host Tyler Menichiello is joined by Sean Tucker, Ph.D., founder and chief scientific officer at Vaxart, a company developing oral recombinant pill vaccines. They discuss Vaxart’s manufacturing process and how it differs from traditional biopharmaceutical production, as well as the regulatory considerations aro…

1
211: When the Innovator Becomes the Patient: Manufacturing Reality vs. Patient Urgency with Jesús Zurdo - Part 1 21:25

27d ago21:25

21:25

Real progress in cell and gene therapy shouldn’t be measured solely by scientific innovation, but by whether those innovations actually reach the patients who need them most. In this episode, David Brühlmann sits down with Jesús Zurdo, a scientist who’s spent three decades engineering life-changing biotechnologies, but whose outlook on the field sh…

1
108: Career and Alumni Services 28:48

25d ago28:48

28:48

Takisha Mundy, Director of Career and Alumni Engagement, talks about the work her office does to support students and alumni meet their professional goals and stay connected to the College. Recorded and edited by Quinn Szente from the College's Sound Recording and Music Technology ProgramBy Montgomery County Community College

1
Curing cancer: Daiichi Sankyo's ambitious ADC approach 39:42

28d ago39:42

39:42

Daiichi Sankyo has been pioneering ADCs since 2010, with a pipeline targeting over 30 indications and potentially reaching 400,000 patients. In today’s episode I’m joined by Dr. Markus Kosch, Head of the EU Oncology Business Division at Daiichi Sankyo. A physician by training with a deep academic background in oncology, Markus has spent over two de…

1
210: From Batch to Continuous: Building Innovation Culture in Conservative Biotech Environments with Irina Ramos - Part 2 21:49

28d ago21:49

21:49

From pandemic-speed vaccine deployment to AI-powered process control, what separates hype from real manufacturing transformation? The biotech industry faces a fundamental challenge: how do you maintain rigorous quality standards while accelerating development timelines, personalizing therapies, and adopting transformative technologies? The answer i…

1
209: From Batch to Continuous: Building Innovation Culture in Conservative Biotech Environments with Irina Ramos - Part 1 29:14

1M ago29:14

29:14

The biotech industry operates under constant tension: we work with products that directly impact human lives, demanding rigorous controls and validation at every step. Yet standing still means falling behind. The question isn't whether to innovate, it's how to do it without compromising the quality and safety standards that define our industry. Iri…

1
How to succeed at BIO-Europe: DISCO Pharma takes us behind the scenes 28:23

1M ago28:23

28:23

Two weeks ago, the biopharma industry gathered in Vienna, Austria, for BIO-Europe. Tens of thousands of one-on-one meetings were organized between innovators and out-licensors with top pharma companies and venture capitalists eager to partner and invest. For the large pharma firms, it’s a chance to learn about new science and keep tabs on evolving …

1
208: Cryogenic Infrared Ion Spectroscopy: From Mass Spec Limitations to Molecular Precision with Tom Rizzo - Part 2 22:37

1M ago22:37

22:37

What if you could analyze every metabolite, glycan variant, and unknown impurity in your bioprocess sample—not just the targets you're looking for, but everything that's actually there? Cryogenic infrared ion spectroscopy combined (CIRIS) with AI-powered analysis transforms untargeted screening from aspiration to reality. This episode moves from fu…

1
Improvements in Batteries, Trains, and Wave Technology 10:04

1M ago10:04

10:04

Disclaimer: This episode was produced when the laboratory operated as the National Renewable Energy Laboratory (NREL). The laboratory is now the National Laboratory of the Rockies (NLR). New week, new discoveries! In today’s episode, you can: Explore the evolving world of battery safety research—from new energy storage technologies to a strategic a…

1
Lessons In Scaling Regenerative Medicine Manufacturing With Organogenesis's Patrick Bilbo 43:32

1M ago43:32

43:32

In this episode of "Better Biopharma," Tyler Menichiello is joined by Patrick Bilbo, chief operating officer at Organogenesis, a regenerative medicine company developing and manufacturing advanced wound care products. They discuss the construction of Organogenesis's new facility in Rhode Island, as well as how the industry has changed in the compan…

1
Smarter Design Controls with AI - Is It Possible? 35:45

1M ago35:45

35:45

Design controls have long been the backbone of safe, compliant medical device development - but artificial intelligence is changing how teams manage them. In this episode of Life Science Solutions, host Chris Adkins sits down with Nick Ciccarelli, Chief Technology Officer at Kymanox, to explore how AI is transforming design controls, the structured…

1
207: Cryogenic Infrared Ion Spectroscopy: From Mass Spec Limitations to Molecular Precision with Tom Rizzo - Part 1 22:35

1M ago22:35

22:35

What if you could identify every structural variant in your biologics—without ambiguity, without massive sample requirements, and without the guesswork that plagues traditional mass spectrometry? Cryogenic infrared ion spectroscopy (CIRIS) makes it possible, transforming molecular characterization from frustrating puzzle to precise science. Today's…

1
107: Biotechnology and Biomanufacturing at Montgomery County Community College 18:53

1M ago18:53

18:53

Dr. Margaret Bryans, Biology Professor and coordinator of the Biotechnology Program at MCCC, talks about her recent BioBuzz Workforce Champion of the Year Award, and gives an overview of her work to educate and train biotechnology and biomanufacturing of students for the Philadelphia region’s science workforce. Recorded by Quinn Szente and Ian Mera…

1
Meet Fusix Biotech: 2025 BIO-Europe Startup Spotlight champion revolutionizing oncology 32:42

1M ago32:42

32:42

Last week saw more than 5,900 people from 3,200 companies gather in Vienna, Austria, for the continent’s largest biopharma partnering conference, BIO-Europe. Over three days the world’s top pharma companies, most innovative biotechs, and life science professionals from 60 countries took more than 32,000 one-on-one meetings, made the connections, an…

1
206: Process Economics Decoded: How to Model Biomanufacturing Costs From Clinical to Commercial Scale with Niklas Jungnelius - Part 2 17:45

2M ago17:45

17:45

Carbon neutrality goals are everywhere in biopharma. But how do you actually measure and reduce your true environmental impact when data gaps and baseline differences make comparisons so tough? In this episode, David Brühlmann talks with Niklas Jungnelius, Cytiva’s expert in process modeling and sustainability, who’s spent years uncovering what rea…

1
What Million Things are Circulating Inside You? with Jenna Hua 51:55

1M ago51:55

51:55

Pollution isn’t an abstract headline; it’s inside our bodies today. We sit down with Dr. Jenna Hua to reveal how small, everyday choices expose us to hormone-disrupting chemicals. Jenna explains why single-chemical research fails in a world of mixed exposures and shows how metabolomics turns invisible toxins into clear, personal insights you can ac…

1
205: Process Economics Decoded: How to Model Biomanufacturing Costs From Clinical to Commercial Scale with Niklas Jungnelius - Part 1 25:35

2M ago25:35

25:35

Your Manufacturing Decisions Are Costing You More Than You Think Every bioreactor decision. Every scale-up choice. Every facility investment. They're all silently writing checks your process might not be able to cash. The difference between a profitable biologics program and one that bleeds capital? Process economic modeling, the analytical framewo…

1
Next‑generation UTI diagnostics: delivering results in just 35 minutes 39:22

2M ago39:22

39:22

Urinary Tract infections, or UTIs, affect millions worldwide, driving sepsis, antibiotic overuse, and microbial resistance. Current diagnostics rely on either slow lab cultures or unreliable dipsticks, and often lead to delayed or unnecessary treatment. Llusern’s Lodestar DX changes that: a point-of-care test that detects 96% of key UTI pathogens i…

1
204: Mastering CRO Selection: Essential Questions for CMC Analytical Development with Daniel Galbraith - Part 2 20:13

2M ago20:13

20:13

Cell and gene therapies are transforming modern medicine, but their path to market is fast and complex. They often jump from small trials to global launch at record speed, putting pressure on analytics, supply chains, and partnerships. Success depends on making smart choices about what to build in-house and what to entrust to expert partners. Danie…

1
Navigating The Complexity of Conditionally Active Biologics With Bonum Therapeutics' Diane Hollenbaugh, Ph.D., and Neela Patel, Ph.D. 47:49

2M ago47:49

47:49

In this episode of "Better Biopharma," host Tyler Menichiello is joined by Bonum Therapeutics' chief scientific officer, Diane Hollenbaugh, Ph.D., and chief business officer, Neela Patel, Ph.D. They talk about the inherent challenges of developing complex molecules like conditionally active biologics, sharing advice on CMC strategy, analytical meth…

1
203: Mastering CRO Selection: Essential Questions for CMC Analytical Development with Daniel Galbraith - Part 1 28:40

2M ago28:40

28:40

Finding an analytical CRO that's truly invested in your success, not just processing samples, makes all the difference in CMC development. In this episode, host David Brühlmann talks with Daniel Galbraith, Chief Scientific Officer at Solvias, about the essential questions and mindset that lead to breakthrough CRO partnerships. With nearly three dec…

1
106: Caribbean Paradise restaurant entrepreneur and community college graduate- Patrick Howell 16:23

2M ago16:23

16:23

Community college graduate Patrick Howell talks about his long career and the pathway that led to him opening a successful chain of Jamaican food restaurants and food trucks. He also talks about his career as a police office, doctor, teacher and school administrator. Recorded and edited by Ian Meranus, from the College's Sound Recording and Music T…

1
How AI Is revolutionizing synthetic biology and biomanufacturing 38:27

2M ago38:27

38:27

Today, I’m joined by Héctor García Martín, a Staff Scientist at Lawrence Berkeley National Laboratory. A pioneer in metabolic engineering and computational biology, Héctor has spent over a decade decoding microbial systems, everything from termite guts to genome-scale flux models, to unlock sustainable biomanufacturing. Now, he’s leading the charge…

1
202: Fighting Antimicrobial Resistance: How AI Cuts Phage Therapy Access from 6 Months to 5 Days with José Bila - Part 2 24:00

2M ago24:00

24:00

What if the answer to battling antibiotic-resistant infections isn’t a new antibiotic, but harnessing viruses that have been quietly dominating bacterial populations? Bacteriophages, viruses that target and kill bacteria, have been saving lives for a century, but their true potential is only now being unlocked by modern machine learning. The race i…

1
201: Fighting Antimicrobial Resistance: How AI Cuts Phage Therapy Access from 6 Months to 5 Days with José Bila - Part 1 24:46

2M ago24:46

24:46

Antibiotic resistance isn’t just a looming problem. It’s a global crisis. Every year, more than one million people die directly from resistant infections, and another 5 million die indirectly. Routine infections are becoming life-threatening, and healthcare systems worldwide are under pressure. Despite decades of warnings, pharmaceutical solutions …

1
Pichia pastoris: the microbial protein expression platform you’re probably underestimating 36:02

2M ago36:02

36:02

Today we’re diving into the world of expression systems with Iskandar Dib, of Validogen and we’ll explore the remarkable potential of Pichia pastoris, a methylotrophic yeast that’s revolutionizing pharmaceutical protein production and beyond. From industrial enzymes to biomaterials, food, feed, and diagnostics, Pichia offers a reliable, scalable, a…

1
200: Mastering Quality by Design: From Product Failures to Commercial Success in Biologics CMC Development - Part 2 20:32

2M ago20:32

20:32

Your process works perfectly at two-liter bench scale. Then you hit fifty liters and titer drops 20%. By two hundred liters, aggregation appears and charge variants shift. Your management team asks: "How long to fix this?" The honest answer? Three to twelve month, because you're flying blind. In Part 2 of this Quality by Design Master Class, David …

1
Developing Antibodies To Block Neuroinflammation With MindImmune's Stevin Zorn, Ph.D. 44:28

2M ago44:28

44:28

In this episode of "Better Biopharma," host Tyler Menichiello is joined by MindImmune's president and CEO, Stevin Zorn, Ph.D. They discuss the development of the company's lead candidate, MITI-101, a monoclonal antibody designed to prevent peripheral immune cells from entering the brain and driving neuroinflammation linked to Alzheimer's disease. F…

1
199: Mastering Quality by Design: From Product Failures to Commercial Success in Biologics CMC Development - Part 1 21:28

2M ago21:28

21:28

Over 40% of biotherapeutic failures during clinical development stem from stability problems—and most trace back to protein aggregation that could have been prevented. In this episode of the Smart Biotech Scientist Podcast, David Brühlmann exposes the hidden manufacturing crisis that derails promising biologics programs and delivers the systematic …

1
Beyond 200 mg/mL: The Science and Scaling of High-Dose Biologics 30:53

2M ago30:53

30:53

Pushing biologics beyond 200 mg/mL isn’t just a formulation challenge - it’s a delivery, manufacturing, and regulatory challenge too. Aggregation, precipitation, and sky-high viscosity make scaling these therapies a gauntlet for drug developers. In this episode of Life Science Solutions, host Chris Adkins continues the conversation on hyper-concent…

1
Biotech royalty deals on the rise and here to stay 51:18

2M ago51:18

51:18

In today's episode, we welcome Clarke Futch, Chairman and CEO of HealthCare Royalty Partners, or HCRx. HCRx are pioneers in royalty-based financing, with a thirty year track record in biopharma investing. Clarke has led more than 60 royalty acquisitions totaling nearly $4 billion and raised over $8 billion across various vehicles, executing more th…

1
198: Mastering ADC Development: CDMO Strategies for Analytics and Scale-Up with Amanda Hoertz - Part 2 21:57

2M ago21:57

21:57

What happens when the most complex molecules in biotech meet the organizational challenge of managing 300+ analytical scientists? The answer lies not just in the science, but in building systems that turn technical complexity into reliable delivery. In Part 2 of our deep dive with Amanda Hoertz, VP of Analytical and Formulation Sciences at KBI Biop…

1
105: Culinary and Baking and Pastry Arts careers- Bistro 1964 and Bakery 340 open at MCCC's Hospitality Institute 24:58

2M ago24:58

24:58

The Hospitality Institute’s two new food options, Bistro 1964 and Bakery 340, are now open for the fall semester for students, employees and community members. Dr. Anthony Ginexi, Dean of Business and Professional Studies, and Jackie Faillace, Operations and Events Manager at the Hospitality Institute, talk about what customers can expect if they s…

1
197: Mastering ADC Development: CDMO Strategies for Analytics and Scale-Up with Amanda Hoertz - Part 1 25:58

3M ago25:58

25:58

What if the key to unlocking ADC manufacturing success lies in abandoning the platform mindset entirely? Antibody-drug conjugates represent biotech's most promising weapon against cancer: precision-targeted therapeutics that deliver cytotoxic payloads directly to tumor cells while sparing healthy tissue. But beneath the clinical promise lies a manu…

1
High Stakes, High Concentrations: Inside Biologics Innovation (Part 1) 30:18

3M ago30:18

30:18

In today’s pharma landscape, patient convenience and drug delivery innovation go hand in hand. But how do you deliver life-saving biologics at higher concentrations without sacrificing safety, stability, or patient comfort? In this live-recorded episode of Life Science Solutions, host Chris Adkins sits down with Ryan Doxey, Vice President of Techni…

1
Contraline's ADAM in the clinic: towards a new era of male contraception? 40:33

3M ago40:33

40:33

When it comes to contraception, most of the innovation in the last century has focused on providing contraceptive alternatives for women. The contraceptive pill was approved by the FDA in 1960, the first IUD approved in 1968, and the female condom in 1993. For men, however, there has been little advancement since the invention of the rubber condom …

1
196: Monolithic Chromatography Innovations: Solving High-Capacity Purification for Gene Therapy Vectors with Alois Jungbauer - Part 2 25:04

3M ago25:04

25:04

What if solving tomorrow’s bioprocessing challenges meant questioning the very physics of chromatography and reimagining downstream processing from the ground up? For years, large biomolecules like viral vectors and exosomes have squeezed through the limitations of traditional chromatography, leaving scientists to wrestle with capacity trade-offs a…